Apellis Pharmaceuticals SG&A Expense (TTM) Analysis

Apellis Pharmaceuticals Inc (APLS)

27.51 -0.55 (-1.96%) USD | NASDAQ | Oct 04, 16:00

27.60 +0.09 (+0.33%) After-Hours: 20:00

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2015. Upgrade now.

Date	Value
June 30, 2024	544.94M
March 31, 2024	528.23M
December 31, 2023	500.82M
September 30, 2023	443.48M
June 30, 2023	376.24M
March 31, 2023	328.07M
December 31, 2022	277.16M
September 30, 2022	234.26M
June 30, 2022	201.62M
March 31, 2022	187.38M
December 31, 2021	176.77M
September 30, 2021	179.80M
June 30, 2021	171.03M
March 31, 2021	150.48M
December 31, 2020	139.40M
September 30, 2020	122.38M
June 30, 2020	104.02M

Date	Value
March 31, 2020	88.38M
December 31, 2019	67.05M
September 30, 2019	45.97M
June 30, 2019	33.60M
March 31, 2019	26.77M
December 31, 2018	22.64M
September 30, 2018	21.11M
June 30, 2018	16.91M
March 31, 2018	12.68M
December 31, 2017	10.46M
September 30, 2017	6.690M
June 30, 2017	5.619M
March 31, 2017	6.951M
December 31, 2016	6.543M
September 30, 2016	6.481M
December 31, 2015	6.151M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

67.05M

Minimum

Dec 2019

544.94M

Maximum

Jun 2024

253.76M

Average

187.38M

Median

Mar 2022

SG&A Expense (TTM) Benchmarks